ARQT Stock Price, News, Filings & Events — Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics, Inc. (ARQT) is a commercial-stage biopharmaceutical company that focuses on developing innovative treatments in the field of immuno-dermatology. Their primary product is ZORYVE® (roflumilast) cream, which is used to treat various skin conditions, including atopic dermatitis. The company aims to provide effective, non-steroidal treatments that can improve the quality of life for patients suffering from chronic inflammatory skin diseases. Arcutis generates revenue primarily through the sale of its products to healthcare providers, pharmacies, and ultimately patients. The company targets both adults and children with skin conditions, making their products relevant to a wide demographic. By addressing unmet medical needs in dermatology, Arcutis positions itself as a valuable player in the healthcare market, appealing to both patients seeking relief and healthcare professionals looking for effective treatment options.

The most recent material news for ARQT.NASDAQ includes the following top three items: 1. FDA Accepts Supplemental New Drug Application for ZORYVE® (July 8, 2026) - Summary : The FDA accepted Arcutis' supplemental New Drug Application (sNDA) for ZORYVE® (roflumilast) cream 0.05% to expand its indication for the treatment of mild to moderate atopic dermatitis in infants down to 3 months. The target action date is set for February 23, 2027. - Importance : This expansion could significantly increase the market for ZORYVE, as it addresses a critical need for treatment options in a vulnerable population. If approved, it could lead to increased sales and market share in the pediatric dermatology segment. 2. Appointment of Chris Peetz to the Board of Directors (July 16, 2026) - Summary : Arcutis announced the appointment of Chris Peetz to its Board of Directors, effective July 15, 2026. Peetz has a strong background in leading biopharmaceutical companies through expansion and product development. - Importance : The addition of Peetz brings valuable expertise to the board, which could enhance strategic decision-making and drive growth initiatives. This could positively influence investor confidence and the company's future performance. 3. Second Quarter 2026 Financial Results Announcement (Scheduled for August 5, 2026) - Summary : Arcutis is set to report its second quarter 2026 financial results and host a conference call on August 5, 2026. - Importance : This upcoming earnings report will provide insights into the company's financial health, product performance, and strategic d...

- Strong Revenue Growth : In Q1 2026, Arcutis reported net product revenue for ZORYVE® (roflumilast) of $105.4 million, a 65% increase compared to Q1 2025, indicating robust demand and market acceptance of their leading product. - Regulatory Advancements : The FDA has accepted a supplemental New Drug Application for ZORYVE® to expand its indication for the treatment of mild to moderate atopic dermatitis in infants down to 3 months, with a target action date of February 23, 2027. This could significantly broaden their market reach. - Innovative Pipeline : Arcutis is advancing its pipeline with the initiation of a Phase 1 trial for ARQ-234, a biologic candidate for atopic dermatitis, which could provide additional growth avenues beyond ZORYVE®. - Strategic Leadership Appointment : The recent appointment of Chris Peetz to the Board of Directors brings valuable experience in leading biopharmaceutical companies through expansion, which could enhance strategic decision-making and operational execution. - Market Positioning : ZORYVE® has received strong recommendations in the American Academy of Dermatology guidelines for pediatric atopic dermatitis, reinforcing its efficacy and safety profile, which could drive further adoption among healthcare providers. - Upcoming Financial Reporting : Arcutis is set to report its Q2 2026 financial results on August 5, 2026, which may provide further insights into growth trends and operational performance, potentially influencing investor sentiment positively.

The bear case for ARQT.NASDAQ includes the following risks: - Regulatory Approval Risks : The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of February 23, 2027, for the supplemental New Drug Application for ZORYVE® (roflumilast) cream. Any delays or rejections could significantly impact the company's growth prospects and revenue. - Market Competition : Arcutis operates in a competitive landscape for dermatological treatments. The introduction of new products by competitors or advancements in existing therapies could erode ZORYVE's market share. - Dependence on ZORYVE Revenue : A significant portion of Arcutis' revenue comes from ZORYVE. If sales do not meet expectations or if there is a decline in demand, it could adversely affect the company's financial health. - Pipeline Development Risks : The company is advancing its pipeline, including a Phase 1 trial for ARQ-234. Any setbacks in clinical trials or failure to demonstrate efficacy could hinder future product launches and revenue streams. - Financial Performance Volatility : Recent financial results showed a 17% decrease in net product revenue compared to the previous quarter. Continued fluctuations in revenue could raise concerns among investors regarding the company's financial stability. - Management and Strategic Execution : Changes in management or strategic direction, such as the recent appointment of Chris Peetz to the Board of Directors, could lead to uncertainty about the company's future plans and execution capabilities.

Upcoming catalysts that could move ARQT.NASDAQ in the next 6-12 months include: 1. Second Quarter 2026 Financial Results : - Date : August 5, 2026 - Details : Arcutis will report its financial results and provide a business update, which could impact investor sentiment based on performance metrics. 2. FDA Action on ZORYVE® (roflumilast) Cream : - PDUFA Target Action Date : February 23, 2027 - Details : The FDA has accepted a supplemental New Drug Application (sNDA) to expand the indication for ZORYVE to treat mild to moderate atopic dermatitis in infants as young as 3 months. This decision could significantly affect the market potential for ZORYVE. 3. Product Launches and Pipeline Developments : - Ongoing : Arcutis is advancing its pipeline, including the initiation of a Phase 1 trial for ARQ-234, a biologic candidate for atopic dermatitis. Progress in clinical trials and potential new product launches could serve as catalysts. These events are critical as they may influence Arcutis's financial performance and market position in the biopharmaceutical sector.

The most recent earnings call for Arcutis Biotherapeutics (ARQT.NASDAQ) was held on May 6, 2026. Management emphasized strong product revenue driven by demand for ZORYVE® (roflumilast) and advancements in their pipeline, including the submission of a supplemental New Drug Application (sNDA) for ZORYVE. The overall tone was optimistic, highlighting growth and strategic initiatives. Key Points from the Earnings Call: - Emphasis on Revenue Growth : - Q1 2026 net product revenue for ZORYVE was $105.4 million, a 65% increase compared to Q1 2025. - Continued strong demand for ZORYVE despite typical Q1 seasonality. - Pipeline Advancements : - Initiation of a Phase 1 trial for ARQ-234, a biologic candidate for atopic dermatitis. - Submission of an sNDA to expand ZORYVE's indication to patients as young as 3 months. - Strategic Focus : - Management discussed the importance of expanding treatment options for atopic dermatitis, particularly for infants. Tone: - The overall tone was positive and forward-looking, with a focus on growth and innovation in immuno-dermatology. Management appeared confident in their strategies and the potential for future product development.